Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Short Interest Update

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) saw a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 14,900 shares, a drop of 71.8% from the March 15th total of 52,800 shares. Based on an average daily volume of 146,500 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the company are short sold.

Shionogi & Co., Ltd. Stock Performance

Shares of OTCMKTS:SGIOY traded up $0.15 during trading on Friday, reaching $8.28. The stock had a trading volume of 49,877 shares, compared to its average volume of 131,201. The company has a quick ratio of 7.01, a current ratio of 7.64 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $7.59 and a two-hundred day simple moving average of $7.21. The firm has a market capitalization of $14.09 billion, a price-to-earnings ratio of 13.86, a P/E/G ratio of 2.37 and a beta of 0.21. Shionogi & Co., Ltd. has a 52 week low of $6.22 and a 52 week high of $8.33.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings results on Friday, January 31st. The company reported $0.16 earnings per share (EPS) for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 12.02%. As a group, analysts anticipate that Shionogi & Co., Ltd. will post 0.66 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.